Drug Trial Radar · NCT00535574
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Nov 2008
Primary completion
Dec 2010
Study completion May 2011
Sponsor
- Lead sponsor
- Beersheva Mental Health CenterGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Sep 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases. The present study is based on: evidence that retinoids are involved in neurodevelopment ("the retinoid dysregulation hypothesis"); an assumption that the combined effect of antipsychotic agents and bexarotene will have a beneficial effect on schizophrenia patients; and the positive findings from our pilot open-label clinical trial (ClinicalTrials.gov Identifier: NCT00141947). However, clinical efficacy of bexarotene should be investigated in a placebo-controlled trial. Methods: In a 6-week, randomized, double-blind placebo-controlled trial Targretin (75 mg/day) or placebo capsules will be added to the stable ongoing antipsychotic treatment of 90 schizophrenia patients. Participants will be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research instruments will be used for assessment of psychopathology, side effects, general functioning and quality of life. In addition, cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count will be monitored at baseline and during the study
Conditions
- Schizophrenia
Interventions
Bexarotene (Targretin LGD1069)Drug
75 mg per day for 6 weeks
bexaroteneDrug
75 mg/day 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- PANSS, CDSS, GAF, QLSTime frame: every two weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Abarbanel Mental Health Center
Bat Yam, Israel
Sha'ar Menashe Mental Health Center,
Hadera, Israel
Be'er Sheva Mental Health Center
Beersheba, Be'er Sheva, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.